Arginine Restores CAR T Cell Function After Heat Stress in Experiments

CAR T cell therapy engineers a patient's immune cells to attack cancer but can trigger cytokine release syndrome, a potentially serious inflammatory reaction. Fever is a hallmark of this reaction. This study suggests sustained high fever may also undermine the treatment itself and identifies arginine, an amino acid, as a possible way to protect cancer fighting activity.

Researchers retrospectively examined patients with B cell acute lymphoblastic leukemia who received CAR T cells targeting CD22. Sustained high fever correlated with poorer clinical response. They then used laboratory experiments to investigate how elevated temperatures affected these engineered immune cells and whether adding arginine could reverse the damage. The abstract also reports testing manufactured therapeutic cells and oral supplementation in vivo.

Heat exposure weakened early activation signals, reduced cancer cell killing, and disrupted cellular energy management alongside altered arginine metabolism. Adding arginine restored function after heat stress and improved killing activity at normal temperatures. These effects depended on mTOR signaling, recruitment of the eIF4F protein production machinery, and metabolic changes driven by c-MYC. Arginine also enhanced cells manufactured under clinical production standards, while oral supplementation improved efficacy in vivo.

The findings point to a potentially modifiable weakness in cancer immunotherapy rather than an established supplement recommendation. Arginine might eventually support treatment performance, but the abstract does not demonstrate that oral supplementation improves outcomes in patients. Patients receiving CAR T therapy should discuss supplements with their oncology team and promptly report fever rather than treating themselves.

This summary is based on the abstract only. Patient numbers, fever thresholds, supplement doses, effect sizes, and detailed safety results are unavailable. The retrospective association cannot establish that fever causes treatment failure, and the species used for the oral supplementation experiments is not specified. Prospective clinical trials are needed to establish whether supplementation benefits patients safely during treatment.